UBS Group Upgrades FRESENIUS SE &/S (FSNUY) to Neutral

UBS Group upgraded shares of FRESENIUS SE &/S (OTCMKTS:FSNUY) from a sell rating to a neutral rating in a research report released on Wednesday, reports.

FSNUY has been the subject of several other research reports. Goldman Sachs Group raised shares of FRESENIUS SE &/S from a neutral rating to a buy rating in a research note on Tuesday, December 18th. Zacks Investment Research cut shares of FRESENIUS SE &/S from a hold rating to a sell rating in a research note on Tuesday, December 18th.

Shares of OTCMKTS FSNUY opened at $12.35 on Wednesday. FRESENIUS SE &/S has a 12-month low of $11.00 and a 12-month high of $22.05. The stock has a market cap of $27.85 billion, a P/E ratio of 13.42, a price-to-earnings-growth ratio of 1.42 and a beta of 1.25. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.18 and a quick ratio of 0.92.

FRESENIUS SE &/S (OTCMKTS:FSNUY) last announced its quarterly earnings data on Wednesday, October 31st. The company reported $0.23 earnings per share (EPS) for the quarter. FRESENIUS SE &/S had a net margin of 5.91% and a return on equity of 12.53%. The company had revenue of $9.52 billion during the quarter. As a group, equities analysts forecast that FRESENIUS SE &/S will post 0.97 earnings per share for the current year.

FRESENIUS SE &/S Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.

Featured Story: What is an SEC Filing?

Receive News & Ratings for FRESENIUS SE &/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FRESENIUS SE &/S and related companies with's FREE daily email newsletter.

Leave a Reply